207
Participants
Start Date
September 29, 2012
Primary Completion Date
June 30, 2015
Study Completion Date
January 8, 2020
Crizotinib
250 mg two times daily \[BID\], oral, on a continuous daily dosing schedule. Cycles are defined in 21 day periods.
Pemetrexed/Cisplatin
Option 1: Pemetrexed/Cisplatin; Pemetrexed, 500 mg/m\^2, will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on Day 1 of a 21-day cycle. Cisplatin, 75 mg/m\^2 will be administered by infusion after adequate hydration according to institutional practices beginning approximately 30 minutes after the end of the pemetrexed infusion. Pemetrexed and cisplatin will be repeated every 3 weeks for a maximum of 6 cycles.
Pemetrexed/Carboplatin
Option 2: Pemetrexed/Carboplatin. Pemetrexed, 500 mg/m\^2, will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on Day 1 of a 21-day cycle. Carboplatin, at a dose calculated to produce an AUC of 5 or 6 mg.min/mL will be administered by infusion according to institutional practices beginning approximately 30 minutes after the end of the pemetrexed infusion. Pemetrexed and carboplatin will be repeated every 3 weeks for a maximum of 6 cycles.
Pamela Youde Nethersole Eastern Hospital, Chai Wan
Queen Mary Hospital, Hong Kong
Chang Gung Medical Foundation, LinKou Branch, Taoyuan District
Chung Shan Medical University Hospital, Taichung
Chi Mei Medical Center Liouying, Liou Ying Township
Chi Mei Medical Center Liuying, Tainan City
Medical Oncology Unit, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Pathumwan
Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Siriraj Hospital,, Bangkok
Hospital Pulau Pinang, George Town
Taipei Veterans General Hospital, Chest Department, Taipei
Department of Nuclear Medicine, Radiotherapy and Oncology, Hospital Universiti Sains Malaysia, Kubang Kerian, Kota Bahru
Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing
Dept. of Respiration. Peking Union Medical College Hospital, Beijing
Peking Union Medical College Hospital, Beijing
307 Hospital of PLA/Department of Lung Cancer, Beijing
Beijing Cancer Hospital, Beijing
The Military General Hospital of Beijing PLA, Beijing
Peking Union Medical College Hospital, Beijing
Chinese PLA General Hospital, Beijing
Chinese PLA General Hospital, Beijing
Beijing Chest Hospital, Capital Medical University, Beijing
Beijing Chest Hospital, Capital Medical University, Beijing
The first hospital of China Medical University/Oncology Department, Shenyang
Department of Oncology, Jilin Provincial Cancer Hospital, Changchun
Shanghai Chest Hospital/Lung cancer clinical center, Shanghai
Shanghai Chest Hospital, Shanghai
Zhongshan Hospital Fudan University / Respiratory Department, Shanghai
Shanghai First People's Hospital, Shanghai
Nanjing General Hospital of Nanjing Military Command, Department of Respiratory medicine, Nanjing
The First Affiliated Hospital of Anhui Medical University, Department of Medical Oncology, Hefei
Tianjin Medical University Cancer Institute and Hospital, Tianjin
Department of Respiratory, The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou
Sir Run Run Shaw Hospital of College of Medicine of Zhejiang University, Center for Oncology, Hangzhou
Fujian Province Oncology Hospital, Fuzhou
Oncology Department, the Second Affiliated Hospital of Third Military Medical University,PLA, Chongqing
Oncology Department, XinQiao Hospital of Third Military Medical University,, Chongqing
Respiration department,the First Affiliated Hospital of Third Military Medical University, PLA, Chongqing
Hunan Provincial Tumor Hospital/Division of Oncology, Changsha
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology/Cancer Center, Wuhan
SUN Yat-Sen University Cancer Center, Guangzhou
Guangdong General Hospital, Oncology Center, Guangzhou
The First Affiliated Hospital of Guangzhou Medical College/Thoracic Surgery, Guangzhou
Department 2 of Chemotherapy, Tumour Hospital of Guangxi Zhuang Autonomous Region, Nanning
Oncology Department, West China Hospital of Sichuan University, Chengdu
Sichuan Province Cancer Hospital/Department of Pulmonary Tumor, Chengdu
Queen Mary Hospital, Hong Kong
Prince of Wales Hospital, Shatin
Lead Sponsor
Pfizer
INDUSTRY